Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H11ClN4O2 |
| Molecular Weight | 242.662 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
InChI
InChIKey=QQHMKNYGKVVGCZ-UHFFFAOYSA-N
InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)
| Molecular Formula | C9H11ClN4O2 |
| Molecular Weight | 242.662 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28979148 | https://www.ncbi.nlm.nih.gov/pubmed/27568360 | https://www.ncbi.nlm.nih.gov/pubmed/28242161 | https://www.drugbank.ca/drugs/DB09343
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28979148 | https://www.ncbi.nlm.nih.gov/pubmed/27568360 | https://www.ncbi.nlm.nih.gov/pubmed/28242161 | https://www.drugbank.ca/drugs/DB09343
Tipiracil is a thymidine phosphorylase inhibitor, that used for the treatment of patients with metastatic colorectal cancer. Tipiracil is used in combination with trifluridine as Lonsurf. Trifluridine is incorporated into DNA via phosphorylation, ultimately inhibiting cell proliferation. Tipiracil increases systemic exposure of trifluridine when coadministered. Lonsurf has recently been approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) who are refractory to or are not considered candidates for, current standard chemotherapy and biological therapy in the EU and USA and in unresectable advanced or recurrent CRC in Japan. The approved regimen of oral twice-daily Lonsurf significantly improved overall survival and progression-free survival and was associated with a significantly higher disease control rate than placebo when added to best supportive care in the multinational, pivotal phase III trial (RECOURSE) and a phase II Japanese trial. Trifluridine/tipiracil was associated with an acceptable tolerability profile, with adverse events generally being managed with dose reductions, temporary interruptions in treatment or administration of granulocyte-colony
stimulating factor. The most common grade 3–4 adverse events (>10 %) were anemia, neutropenia, thrombocytopenia, and leukopenia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3106 |
20.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | LONSURF Approved UseLONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1) Launch Date2015 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
41.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
40 mg/m² 1 times / day multiple, oral dose: 40 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
44.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
50.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
50 mg/m² 1 times / day multiple, oral dose: 50 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
70 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
70 mg/m² 1 times / day multiple, oral dose: 70 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
99.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
161 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
40 mg/m² 1 times / day multiple, oral dose: 40 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
234 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
50 mg/m² 1 times / day multiple, oral dose: 50 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
317 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
70 mg/m² 1 times / day multiple, oral dose: 70 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
447 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
40 mg/m² 1 times / day multiple, oral dose: 40 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
30 mg/m² 1 times / day multiple, oral dose: 30 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.01 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
50 mg/m² 1 times / day multiple, oral dose: 50 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
70 mg/m² 1 times / day multiple, oral dose: 70 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22735906 |
60 mg/m² 1 times / day multiple, oral dose: 60 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered: TRIFLURIDINE |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.4 h |
35 mg/m² 2 times / day steady-state, oral dose: 35 mg/m² route of administration: Oral experiment type: STEADY-STATE co-administered: |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
92% |
35 mg/m² 2 times / day steady-state, oral dose: 35 mg/m² route of administration: Oral experiment type: STEADY-STATE co-administered: |
TIPIRACIL HYDROCHLORIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 mg/m2/day 1 times / day multiple, oral MTD Dose: 50 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 6 Sources: |
Other AEs: Granulocytopenia, Granulocytopenia... Other AEs: Granulocytopenia (grade 4, 50%) Sources: Granulocytopenia (grade 3, 16.7%) |
100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
DLT: Anemia... Other AEs: Granulocytopenia... Dose limiting toxicities: Anemia (grade 3, 50%) Other AEs:Granulocytopenia (grade 4, 100%) Sources: |
60 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 60 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
DLT: Granulocytopenia... Other AEs: Granulocytopenia... Dose limiting toxicities: Granulocytopenia (grade 4, 33.3%) Other AEs:Granulocytopenia (grade 3, 33.3%) Sources: |
180 mg/m2/day 1 times / day multiple, oral Highest studied dose|MTD Dose: 180 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 180 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
DLT: Granulocytopenia... Other AEs: Fatigue, Nausea... Dose limiting toxicities: Granulocytopenia (grade 3-4, 66.7%) Other AEs:Fatigue (grade 1-2, 66.7%) Sources: Nausea (grade 1-2, 50%) Diarrhea (grade 1-2, 16.7%) |
110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
DLT: Granulocytopenia... Other AEs: Fatigue, Nausea... Dose limiting toxicities: Granulocytopenia (grade 3-4, 100%) Other AEs:Fatigue (grade 1-2, 66.7%) Sources: Nausea (grade 1-2, 66.7%) Anorexia (grade 1-2, 66.7%) Diarrhea (grade 1-2, 33.3%) Taste abnormality (grade 1-2, 33.3%) Anemia (grade 1-2, 66.7%) Anemia (grade 3-4, 33.3%) |
100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
Other AEs: Fatigue, Anorexia... Other AEs: Fatigue (grade 3-4, 16.7%) Sources: Anorexia (grade 3-4, 16.7%) Granulocytopenia (grade 3-4, 100%) |
120 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 120 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 120 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 9 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 9 Sources: |
DLT: Granulocytopenia... Dose limiting toxicities: Granulocytopenia (grade 3-4, 33.3%) Sources: |
140 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 140 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 140 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
Other AEs: Anemia... Other AEs: Anemia (grade 3-4, 33.3%) Sources: |
150 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 150 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 150 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
Other AEs: Granulocytopenia... Other AEs: Granulocytopenia (grade 3-4, 33.3%) Sources: |
170 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 170 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 170 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
DLT: Nausea, Granulocytopenia... Dose limiting toxicities: Nausea (grade 3, 66.7%) Sources: Granulocytopenia (grade 3-4, 66.7%) |
70 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 70 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 70 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
DLT: Granulocytopenia... Dose limiting toxicities: Granulocytopenia (grade 3-4, 50%) Sources: |
90 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 90 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 90 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
Other AEs: Granulocytopenia, Anemia... Other AEs: Granulocytopenia (grade 3-4, 100%) Sources: Anemia (grade 3-4, 33.3%) |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.100 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.100 |
Other AEs: GGT increased... Other AEs: GGT increased (grade 3-4, 3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.100 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.101 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.101 |
Other AEs: Diarrhea... Other AEs: Diarrhea (grade 3-4, 3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.101 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.102 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.102 |
Other AEs: Leukopenia... Other AEs: Leukopenia (grade 3-4, 2.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.102 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.103 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.103 |
Other AEs: Platelet count decreased... Other AEs: Platelet count decreased (grade 3-4, 2.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.103 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.104 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.104 |
Other AEs: Dyspnea... Other AEs: Dyspnea (grade 3-4, 2.3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.104 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.105 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.105 |
Other AEs: General physical health deterioration... Other AEs: General physical health deterioration (grade 3-4, 2.3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.105 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.106 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.106 |
Other AEs: Abdominal pain... Other AEs: Abdominal pain (grade 3-4, 2.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.106 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.107 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.107 |
Other AEs: Hypokalemia... Other AEs: Hypokalemia (grade 3-4, 2.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.107 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.108 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.108 |
Other AEs: Thrombocytopenia... Other AEs: Thrombocytopenia (grade 3-4, 2.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.108 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.109 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.109 |
Other AEs: Vomiting... Other AEs: Vomiting (grade 3-4, 2.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.109 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.110 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.110 |
Other AEs: Pyrexia... Other AEs: Pyrexia (grade 3-5, 1.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.110 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.111 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.111 |
Other AEs: Constipation... Other AEs: Constipation (grade 3-5, 0.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.111 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.112 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.112 |
Other AEs: Cough... Other AEs: Cough (grade 3-5, 0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.112 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.113 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.113 |
Other AEs: Edema peripheral... Other AEs: Edema peripheral (grade 3-5, 0.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.113 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.114 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.114 |
Other AEs: Stomatitis... Other AEs: Stomatitis (grade 3-5, 0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.114 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.115 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.115 |
Other AEs: Back pain... Other AEs: Back pain (grade 3-5, 1.7%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.115 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.116 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.116 |
Other AEs: Weight decreased... Other AEs: Weight decreased (grade 3-5, 0.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.116 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.117 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.117 |
Other AEs: Abdominal pain upper... Other AEs: Abdominal pain upper (grade 3-5, 0.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.117 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.118 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.118 |
Other AEs: Ascites... Other AEs: Ascites (grade 3-5, 0.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.118 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.119 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.119 |
Other AEs: Mucosal inflammation... Other AEs: Mucosal inflammation (grade 3-5, 0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.119 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.120 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.120 |
Other AEs: AST increased... Other AEs: AST increased (grade 3-5, 1.1%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.120 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.121 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.121 |
Other AEs: Hyponatremia... Other AEs: Hyponatremia (grade 3-5, 1.3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.121 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.122 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.122 |
Other AEs: Back pain... Other AEs: Back pain (grade 3-5, 1.7%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.122 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.123 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.123 |
Other AEs: Tumor pain... Other AEs: Tumor pain (grade 3-5, 0.6%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.123 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.124 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.124 |
Other AEs: Hypertension... Other AEs: Hypertension (grade 3-5, 1.5%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.124 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.77 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.77 |
Disc. AE: Neutropenia... AEs leading to discontinuation/dose reduction: Neutropenia (3.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.77 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.78 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.78 |
Disc. AE: Anemia... AEs leading to discontinuation/dose reduction: Anemia (1.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.78 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.79 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.79 |
Disc. AE: Febrile neutropenia... AEs leading to discontinuation/dose reduction: Febrile neutropenia (1.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.79 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.80 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.80 |
Disc. AE: Neutrophil count decreased... AEs leading to discontinuation/dose reduction: Neutrophil count decreased (1.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.80 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.81 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.81 |
Disc. AE: Fatigue... AEs leading to discontinuation/dose reduction: Fatigue (1.5%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.81 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.82 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.82 |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (1.3%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.82 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.83 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.83 |
Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (0.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.83 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.84 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.84 |
Disc. AE: Decreased appetite... AEs leading to discontinuation/dose reduction: Decreased appetite (0.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.84 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.85 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.85 |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (0.8%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.85 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.86 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.86 |
Disc. AE: Asthenia... AEs leading to discontinuation/dose reduction: Asthenia (0.6%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.86 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.87 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.87 |
Disc. AE: Mucosal inflammation... AEs leading to discontinuation/dose reduction: Mucosal inflammation (0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.87 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.88 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.88 |
Disc. AE: Blood alkaline phosphatase increased... AEs leading to discontinuation/dose reduction: Blood alkaline phosphatase increased (0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.88 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.89 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.89 |
Disc. AE: Platelet count decreased... AEs leading to discontinuation/dose reduction: Platelet count decreased (0.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.89 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.90 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.90 |
Other AEs: Neutropenia... Other AEs: Neutropenia (grade 3-4, 23.8%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.90 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.91 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.91 |
Other AEs: Neutrophil count decreased... Other AEs: Neutrophil count decreased (grade 3-4, 18.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.91 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.92 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.92 |
Other AEs: Anemia... Other AEs: Anemia (grade 3-4, 15.6%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.92 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.93 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.93 |
Other AEs: White blood cell count decreased... Other AEs: White blood cell count decreased (grade 3-4, 10.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.93 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.94 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.94 |
Other AEs: Fatigue... Other AEs: Fatigue (grade 3-4, 3.9%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.94 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.95 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.95 |
Other AEs: Blood bilirubin increased... Other AEs: Blood bilirubin increased (grade 3-4, 3.8%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.95 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.96 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.96 |
Other AEs: Febrile neutropenia... Other AEs: Febrile neutropenia (grade 3-4, 3.8%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.96 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.97 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.97 |
Other AEs: Decreased appetite... Other AEs: Decreased appetite (grade 3-4, 3.6%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.97 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.98 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.98 |
Other AEs: Asthenia... Other AEs: Asthenia (grade 3-4, 3.4%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.98 |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.99 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.99 |
Other AEs: Blood alkaline phosphatase increased... Other AEs: Blood alkaline phosphatase increased (grade 3-4, 3.2%) Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.99 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Granulocytopenia | grade 3, 16.7% | 50 mg/m2/day 1 times / day multiple, oral MTD Dose: 50 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 6 Sources: |
| Granulocytopenia | grade 4, 50% | 50 mg/m2/day 1 times / day multiple, oral MTD Dose: 50 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 6 Sources: |
| Anemia | grade 3, 50% DLT |
100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 4, 100% | 100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3, 33.3% | 60 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 60 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 4, 33.3% DLT |
60 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 60 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 60 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 54 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 54 years Sex: M+F Population Size: 3 Sources: |
| Diarrhea | grade 1-2, 16.7% | 180 mg/m2/day 1 times / day multiple, oral Highest studied dose|MTD Dose: 180 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 180 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Nausea | grade 1-2, 50% | 180 mg/m2/day 1 times / day multiple, oral Highest studied dose|MTD Dose: 180 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 180 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Fatigue | grade 1-2, 66.7% | 180 mg/m2/day 1 times / day multiple, oral Highest studied dose|MTD Dose: 180 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 180 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Granulocytopenia | grade 3-4, 66.7% DLT |
180 mg/m2/day 1 times / day multiple, oral Highest studied dose|MTD Dose: 180 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 180 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Diarrhea | grade 1-2, 33.3% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Taste abnormality | grade 1-2, 33.3% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Anemia | grade 1-2, 66.7% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Anorexia | grade 1-2, 66.7% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Fatigue | grade 1-2, 66.7% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Nausea | grade 1-2, 66.7% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3-4, 100% DLT |
110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Anemia | grade 3-4, 33.3% | 110 mg/m2/day 1 times / day multiple, oral MTD Dose: 110 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 110 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3-4, 100% | 100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Anorexia | grade 3-4, 16.7% | 100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Fatigue | grade 3-4, 16.7% | 100 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 100 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 100 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Granulocytopenia | grade 3-4, 33.3% DLT |
120 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 120 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 120 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 9 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 9 Sources: |
| Anemia | grade 3-4, 33.3% | 140 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 140 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 140 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3-4, 33.3% | 150 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 150 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 150 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Nausea | grade 3, 66.7% DLT |
170 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 170 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 170 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3-4, 66.7% DLT |
170 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 170 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 170 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Granulocytopenia | grade 3-4, 50% DLT |
70 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 70 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 70 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 6 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 6 Sources: |
| Granulocytopenia | grade 3-4, 100% | 90 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 90 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 90 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| Anemia | grade 3-4, 33.3% | 90 mg/m2/day 1 times / day multiple, oral Studied dose Dose: 90 mg/m2/day, 1 times / day Route: oral Route: multiple Dose: 90 mg/m2/day, 1 times / day Sources: |
unhealthy, median age 59 years n = 3 Health Status: unhealthy Condition: solid tumors Age Group: median age 59 years Sex: M+F Population Size: 3 Sources: |
| GGT increased | grade 3-4, 3% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.100 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.100 |
| Diarrhea | grade 3-4, 3% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.101 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.101 |
| Leukopenia | grade 3-4, 2.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.102 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.102 |
| Platelet count decreased | grade 3-4, 2.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.103 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.103 |
| Dyspnea | grade 3-4, 2.3% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.104 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.104 |
| General physical health deterioration | grade 3-4, 2.3% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.105 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.105 |
| Abdominal pain | grade 3-4, 2.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.106 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.106 |
| Hypokalemia | grade 3-4, 2.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.107 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.107 |
| Thrombocytopenia | grade 3-4, 2.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.108 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.108 |
| Vomiting | grade 3-4, 2.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.109 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.109 |
| Pyrexia | grade 3-5, 1.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.110 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.110 |
| Constipation | grade 3-5, 0.2% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.111 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.111 |
| Cough | grade 3-5, 0.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.112 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.112 |
| Edema peripheral | grade 3-5, 0.2% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.113 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.113 |
| Stomatitis | grade 3-5, 0.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.114 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.114 |
| Back pain | grade 3-5, 1.7% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.115 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.115 |
| Weight decreased | grade 3-5, 0.2% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.116 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.116 |
| Abdominal pain upper | grade 3-5, 0.2% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.117 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.117 |
| Ascites | grade 3-5, 0.9% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.118 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.118 |
| Mucosal inflammation | grade 3-5, 0.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.119 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.119 |
| AST increased | grade 3-5, 1.1% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.120 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.120 |
| Hyponatremia | grade 3-5, 1.3% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.121 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.121 |
| Back pain | grade 3-5, 1.7% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.122 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.122 |
| Tumor pain | grade 3-5, 0.6% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.123 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.123 |
| Hypertension | grade 3-5, 1.5% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.124 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.124 |
| Neutropenia | 3.2% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.77 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.77 |
| Anemia | 1.9% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.78 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.78 |
| Febrile neutropenia | 1.9% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.79 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.79 |
| Neutrophil count decreased | 1.9% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.80 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.80 |
| Fatigue | 1.5% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.81 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.81 |
| Diarrhea | 1.3% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.82 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.82 |
| Nausea | 0.9% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.83 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.83 |
| Decreased appetite | 0.9% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.84 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.84 |
| Vomiting | 0.8% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.85 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.85 |
| Asthenia | 0.6% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.86 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.86 |
| Mucosal inflammation | 0.4% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.87 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.87 |
| Blood alkaline phosphatase increased | 0.4% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.88 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.88 |
| Platelet count decreased | 0.4% Disc. AE |
35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.89 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.89 |
| Neutropenia | grade 3-4, 23.8% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.90 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.90 |
| Neutrophil count decreased | grade 3-4, 18.9% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.91 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.91 |
| Anemia | grade 3-4, 15.6% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.92 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.92 |
| White blood cell count decreased | grade 3-4, 10.9% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.93 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.93 |
| Fatigue | grade 3-4, 3.9% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.94 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.94 |
| Blood bilirubin increased | grade 3-4, 3.8% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.95 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.95 |
| Febrile neutropenia | grade 3-4, 3.8% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.96 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.96 |
| Decreased appetite | grade 3-4, 3.6% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.97 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.97 |
| Asthenia | grade 3-4, 3.4% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.98 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.98 |
| Blood alkaline phosphatase increased | grade 3-4, 3.2% | 35 mg/m2 2 times / day multiple, oral Recommended Dose: 35 mg/m2, 2 times / day Route: oral Route: multiple Dose: 35 mg/m2, 2 times / day Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.99 |
unhealthy, median age 63 years n = 533 Health Status: unhealthy Condition: metastatic colorectal cancer Age Group: median age 63 years Sex: M+F Population Size: 533 Sources: Page: nda/2015/207981Orig1s000MedR.pdf - p.99 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| yes | no (co-administration study) Comment: The population PK analysis suggested that concomitant administration of OCT2 inhibitors (n=24) had no effect on the PK parameters of trifluridine and tipiracil. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000ClinPharmR.pdf#page=34 Page: 34.0 |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. | 1998 Feb |
|
| Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening. | 2003 Nov 3 |
|
| Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. | 2004 Feb |
|
| Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor. | 2004 Jan |
|
| Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. | 2004 Jun |
|
| Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. | 2005 May 9 |
|
| Thymidine phosphorylase from Escherichia coli: tight-binding inhibitors as enzyme active-site titrants. | 2006 Feb |
|
| Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. | 2007 Jun |
|
| [Influence of the thymidine phosphorylase (platelet-derived endothelial cell growth factor) on tumor angiogenesis. Catalytic activity of enzyme inhibitors]. | 2010 |
|
| Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. | 2014 Dec |
Patents
Sample Use Guides
In combination with trifluridine, 35 mg/m2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily within one hour of completion of morning and evening meals on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity.
Route of Administration:
Oral
HCT 116, HCT-15, and HT-29 cells were seeded at appropriate concentrations in duplicates in six-well plates. Twenty-four hours after plating, the cells were treated with the trifluridine (FTD 2 mkM or 4 mkM), or IR alone, or the combination of both using the RX-650 CABINET X-Ray system (Faxitron Xray Corp., Wheeling, IL, USA) with 3.4 Gy/min for 0.6-2.4 min. Ten to 12 days after plating, cells were fixed with 20% glutaraldehyde, stained with 0.05% crystal violet, and the number of colonies containing at least 50 cells was determined. Trifluridine enhances the efficacy of IR.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:41:50 GMT 2023
by
admin
on
Sat Dec 16 01:41:50 GMT 2023
|
| Record UNII |
NGO10K751P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
564116
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
||
|
NDF-RT |
N0000191870
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NGO10K751P
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
8696
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
183204-74-2
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL235668
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
C152646
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
4893
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
DB09343
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
N0000191869
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | Thymidine Phosphorylase Inhibitors [MoA] | ||
|
NGO10K751P
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
DTXSID601025833
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
1670304
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
90879
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
SUB174128
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
Tipiracil
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
6323266
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
100000160943
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
9500
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
BC-15
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY | |||
|
m11862
Created by
admin on Sat Dec 16 01:41:50 GMT 2023 , Edited by admin on Sat Dec 16 01:41:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
|
||
|
EXCRETED UNCHANGED |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||
| Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE ADMINISTRATION |
|
||